Azitra (AZTR) investor relations material

Executive summary

• Focused on developing precision dermatology therapies using engineered proteins and live biotherapeutics, leveraging a proprietary microbial library and AI/ML technology for candidate discovery.

• Pipeline includes ATR-COSF (cosmetic ingredient), ATR-01 (ichthyosis vulgaris), ATR-04 (EGFR inhibitor rash), and ATR-12 (Netherton syndrome); clinical progress includes IND clearance, Fast Track designation for ATR-04, and paused enrollment for ATR-12 to preserve capital.

• Reported first preclinical data from ATR-COSF, showing controlled delivery and anti-wrinkle activity in ex vivo human skin, supporting advancement to a proof-of-concept clinical study.

• Advanced recombinant protein initiatives, including TEV Protease and T7 RNA Polymerase, expanding into biotechnology research and manufacturing.

• Strategic partnerships with leading academic centers and exclusive technology licenses support R&D and manufacturing efficiency.

Financial highlights

• Net loss for Q2 2026 was $3.35 million, a 16% increase year-over-year; net loss for the six months ended June 30, 2026 was $7.27 million, up 22% from the prior year.

• Operating expenses for Q2 2026 rose 19% to $3.42 million, driven by a 41% increase in G&A and a 4% decrease in R&D; six-month operating expenses increased 23% to $7.35 million.

• R&D expenses were $1.4 million for Q2 2026, unchanged from Q2 2025; G&A expenses increased to $2.1 million from $1.5 million year-over-year.

• Cash and cash equivalents were $6.7 million as of June 30, 2026, with total assets of $8.9 million and working capital of $5.9 million.

• Net cash used in operating activities for the first half of 2026 was $5.77 million; financing activities provided $10.6 million, mainly from private placements and equity line draws.

Outlook and guidance

• Management expects continued increases in R&D and G&A expenses due to clinical trial activity, product development, and public company costs.

• Human cosmetic application study for ATR-COSF planned to start in Q3 2026; topline data from ATR-04 Phase 1/2 trial expected in Q4 2026.

• Current cash is not sufficient to fund operations for the next twelve months; additional capital will be sought through equity, debt, grants, or partnerships.

• Substantial doubt exists about the ability to continue as a going concern without further financing.

• Strategic pause in ATR-12 Phase 1b trial for Netherton syndrome to focus on higher-priority programs.